5Mes·

Diabetes Care publishes results from the prevalence phase of Corcept's CATALYST study in people with difficult-to-control type 2 diabetes

$CORT (+2,93%)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat serious endocrinologic, oncologic, metabolic and neurologic diseases by modulating the effects of the hormone cortisol, today announced the publication of results from the prevalence phase of the CATALYST study in Diabetes Care , a peer-reviewed journal of the American Diabetes Association.


https://www.wallstreet-online.de/nachricht/19251780-diabetes-care-publishes-results-from-prevalence-phase-of-corcept-s-catalyst-trial-people-with-difficult-to-control-type-2-diabetes

attachment
6
10 Commenti

Nice share, but already wildly volatile. I just keep on holding 💯
1
Visualizza tutti 3 ulteriori risposte
immagine del profilo
Too bad I don't have any more cash 😒
Visualizza tutti 5 ulteriori risposte
Partecipa alla conversazione